CNS Pharmaceuticals (CNSP) Proxy Filing summary

Executive summary

• Special Meeting scheduled for November 26, 2024, to address key proposals impacting capital structure and compliance with Nasdaq listing requirements.

• Proposals include a reverse stock split, warrant repricing, and potential adjournment to solicit more votes if needed.

• Board recommends voting in favor of all proposals to maintain listing and financial flexibility.

Voting matters and shareholder proposals

• Proposal 1: Authorize Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50 within one year.

• Proposal 2: Approve repricing of 2,434,120 investor warrants to the lower of $1.13 or the closing price on approval date, per Nasdaq rules.

• Proposal 3: Authorize adjournment of the meeting to solicit additional proxies if necessary.

• Each proposal requires more votes cast in favor than against; abstentions and broker non-votes have no effect.

Board of directors and corporate governance

• Board retains discretion to implement or delay the reverse stock split even if approved.

• No current plans to use increased authorized shares for anti-takeover purposes; Board not aware of any takeover attempts.